ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Incyte Corporation (INCY) Report Updated: Dec 15, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Incyte Corporation (INCY)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology
Competitors: ANAC, CBST, FOLD, CBPO

Stock Analysis

Rating: Monthly View

A
B
C
D
F
December January February March April May June July August September October November

Rating: Weekly View

This Week: B down downgrade
Last Week: A same upgrade
Two Weeks Ago: B up no change
service keys

Incyte Corporation© quotemedia

Company Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company offers JAKAFI, an oral janus associated kinase inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. The company’s product pipe line includes INCB18424, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies. The company’s products in pipeline also comprise INCB28050 that is in Phase IIb clinical trail for the treatment rheumatoid arthritis and psoriasis; INCB28060 and INCB24360, which are Phase I clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Recent News: Incyte Corporation